









Markets
/
Stocks
/
nasdaq-qncx
/

Quince Therapeutics Inc

QNCX

1.600USD

-0.030-1.84%

Close 11/04, 16:00（ET）Quotes delayed by 15 min

85.80MMarket Cap

LossP/E TTM



Quince Therapeutics Inc

1.600

-0.030-1.84%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Quince Therapeutics Inc

Currency: USD Updated: 2025-10-27

Key Insights

Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Quince Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

245 / 501

Overall Ranking

442 / 4682

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 6 analysts

Buy

Current Rating

7.500

Target Price

+354.55%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Quince Therapeutics Inc Highlights

StrengthsRisks

Quince Therapeutics, Inc. is a late-stage biotechnology company. The Company is engaged in unlocking the patient’s own biology to deliver life-changing therapeutics to those living with rare diseases. Its proprietary autologous intracellular drug encapsulation (AIDE) technology platform is a drug/device combination that uses an automated process designed to encapsulate a drug into the patient’s own red blood cells. The Company’s Phase III lead asset, EryDex, leverages its AIDE technology to encapsulate dexamethasone sodium phosphate (DSP) into a patient’s own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, Ataxia-Telangiectasia (A-T). Its AIDE technology is designed to allow for the chronic administration of drugs that have limitations due to toxicity, poor biodistribution, suboptimal pharmacokinetics, or immune response. The AIDE technology platform delivers a variety of therapeutics, ranging from small to large molecules, as well as biologics.

Undervalued

The company’s latest PE is -1.63, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 11.97M shares, increasing 8.56% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 1.45M shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.12.

Financial Health

Currency: USD Updated: 2025-10-27

There is no financial score for this company; the Biotechnology & Medical Research industry's average is 6.92.

Score

Industry at a Glance

Previous score

0.00

Change



Financials



Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings



Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency



Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential



Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns



Key Metrics

Free cash flow

No Data

Quince Therapeutics Inc's Company Valuation

Currency: USD Updated: 2025-10-27

The company’s current valuation score is 6.90, which is lower than the Biotechnology & Medical Research industry's average of 6.98. Its current P/E ratio is -1.63, which is -84.15% below the recent high of -0.26 and -27.17% above the recent low of -2.08.

Score

Industry at a Glance

Previous score

6.90

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 245/501

No Data

Earnings Forecast

Currency: USD Updated: 2025-10-27

The company’s current earnings forecast score is 8.33, which is higher than the Biotechnology & Medical Research industry's average of 8.04. The average price target for Quince Therapeutics Inc is 8.00, with a high of 10.00 and a low of 4.00.

Score

Industry at a Glance

Previous score

8.33

Change

Support & Resistance

No Data

Analyst Rating

Based on 6 analysts

Buy

Current Rating

7.500

Target Price

+360.12%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

521

Total

Median

Average

Company name

Ratings

Analysts

Quince Therapeutics Inc

QNCX

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

Ionis Pharmaceuticals Inc

IONS

...

104

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-10-27

The company’s current price momentum score is 7.14, which is higher than the Biotechnology & Medical Research industry's average of 6.80. Sideways: Currently, the stock price is trading between the resistance level at 2.10 and the support level at 1.54, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.08

Change

0.06

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(2)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.069

Neutral

RSI(14)

37.297

Neutral

STOCH(KDJ)(9,3,3)

14.705

Oversold

ATR(14)

0.104

Low Volatility

CCI(14)

-127.670

Sell

Williams %R

90.909

Oversold

TRIX(12,20)

-0.114

Sell

StochRSI(14)

0.000

Oversold

Moving Average

Sell(5)

Neutral(0)

Buy(1)

Indicators

Value

Direction

MA5

1.642

Sell

MA10

1.709

Sell

MA20

1.813

Sell

MA50

1.699

Sell

MA100

1.673

Sell

MA200

1.470

Buy

Institutional Confidence

Currency: USD Updated: 2025-10-27

The company’s current institutional recognition score is 3.00, which is lower than the Biotechnology & Medical Research industry's average of 5.11. The latest institutional shareholding proportion is 22.28%, representing a quarter-over-quarter decrease of 34.25%. The largest institutional shareholder is The Vanguard, holding a total of 1.45M shares, representing 2.71% of shares outstanding, with 6.38% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Lamond (David A.)

4.38M

Nantahala Capital Management, LLC

2.53M

The Vanguard Group, Inc.

Star Investors

1.45M

+13.09%

Sofinnova Partners

1.20M

-50.05%

Thye (Dirk)

1.01M

+17.55%

EPIQ Capital Group, LLC

824.78K

-0.14%

IEQ Capital LLC

439.27K

-45.55%

Geode Capital Management, L.L.C.

396.98K

+0.32%

Renaissance Technologies LLC

Star Investors

379.80K

-24.03%

Hannah (Brendan)

342.39K

+12.39%

Risk Assessment

Currency: USD Updated: 2025-10-27

There is no risk assessment score for the company; the Biotechnology & Medical Research industry's average is 3.49. The company's beta value is 1.07. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.